Core Insights - Izotropic Corporation has announced the issuance of the only U.S. patent for computer-aided diagnosis (CADx) with breast CT, which is covered by an exclusive global license agreement with the Regents of the University of California [1] - The IzoView Breast CT Imaging System is being positioned as a 3D imaging alternative that enhances breast cancer screening, particularly for patients with dense breast tissue [3] - CADx will be integrated into the IzoView system post-market launch as a software upgrade, potentially offered as an incentive to early adopters [5] Company Overview - Izotropic Corporation specializes in medical devices and innovative technologies aimed at improving breast cancer screening, diagnosis, and treatment [1][6] - The company is focused on commercializing the IzoView Breast CT Imaging System, which utilizes a machine-learning image reconstruction algorithm to optimize imaging while maintaining low radiation doses [4] Technology and Market Position - CADx is an AI-based tool designed to assist radiologists in interpreting medical images, addressing limitations of existing imaging modalities like mammography and ultrasound [2] - The integration of CADx aims to enhance diagnostic performance, reduce read times, and improve overall efficiency in clinical workflows [2]